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Summary Hepatocyte growth factor (HGF) has been known as a multiple function factor, which also
stimulates early haematopoiesis. In this study, we found that HGF was expressed at both the RNA and
protein levels in acute myeloid leukaemia (AML) and chronic myeloid leukaemia (CML). In patients with
AML (n = 20) and CML (n = 5), bone marrow plasma HGF concentrations were 20.44 ± 6.26 (mean ± s.e.)
ng ml' and 7.17 ± 0.53 ng ml-' respectively. These were significantly higher (P< 0.01) than the value for
normal subjects (n = 26): mean 0.92 ± 0.09 ng ml-'. Constitutive HGF production was observed in freshly
prepared leukaemic blast cells from three patients with high HGF levels of bone marrow plasma. Expression
of HGF mRNA was correlated with bone marrow plasma HGF levels. After complete remission was obtained
in six patients, bone marrow plasma HGF levels were significantly decreased. In contrast, the HGF mRNA
was less abundantly expressed in acute lymphoid leukaemia (ALL). In patients with ALL (n = 5), bone
marrow plasma HGF concentration (0.69 ± 0.14 ng ml -) remained low within the value for normal subjects.
These results suggest that some populations of myeloid lineage cells have the ability to produce HGF.
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Hepatocyte growth factor (HGF), also known as a scatter
factor (Weidner et al., 1990), was initially identified as a
mitogen for primary cultured adult rat hepatocytes, from rat
platelets (Russell et al., 1984) and from the plasma of
patients with fulminant hepatic failure (Gohda et al., 1986).
It was purified from rat platelets as a disulphide-linked
heterodimeric molecule composed of a 69 kDa a-chain and a
34 kDa ,3-chain (Nakamura et al., 1986, 1987). Molecular
cloning of HGF cDNA revealed that both chains of HGF
are encoded in a single gene (Miyazawa et al., 1989;
Nakamura et al., 1989; Seki et al., 1990; Tashiro et al., 1990).
Accumulating evidence indicates that, in addition to its effect
on hepatocytes, HGF is a unique multifunctional cytokine
acting on a wide variety of cells as a mitogen (Igawa et al.,
1991; Kan et al., 1991; Rubin et al., 1991), a motogen
(Gherardi et al., 1989; Gherardi and Stoker, 1991), a mor-
phogen (Montesano et al., 1991), an angiogenetic factor
(Bussolino et al., 1992; Grant et al., 1993) and a tumour
cytotoxic factor (Higashio et al., 1990); Tajima et al., 1991).
Indeed, HGF mRNA is expressed in various tissues, includ-
ing kidney (Tashiro et al., 1990; Nagaike et al., 1991), heart
(Tashiro et al., 1990), lung (Tashiro et al., 1990; Yanagita et
al., 1992, 1993) and brain (Tashiro et al., 1990), as well as in
injured liver (Kinoshita et al., 1989).
Previous reports have shown that HGF stimulates growth
of haematopoietic progenitor cells derived from mouse
(Kmiecik et al., 1992; Nishino et al., 1995) and human
(Galimi et al., 1994). Of particular interest is HGF receptor
(HGFR)/c-met mRNA expression (Bottaro et al., 1991; Nal-
dini et al., 1991a,b; Giordano et al., 1993) has been reported
in several murine haematopoietic progenitor cell lines
(Kmiecik et al., 1992; Mizuno et al., 1993) and human
haematopoietic progenitor cells (Galimi et al., 1994).
Recently, we reported that the human promyelocytic
leukaemia cell line, HL-60, produces HGF (Nishino et al.,
1991; Inaba et al., 1993). More recently, Nakamura et al.
(1994a) reported that a high level of HGF was detected in
blood and bone marrow plasma of leukaemia patients. These
data strongly suggest the possibility that HGF may play an
important role in haematopoiesis and that it may act as an
autocrine or paracrine growth factor in the development of
leukaemia.
In this study, we determined HGF production and its gene
expression in leukaemic blast cells from myeloid leukaemic
patients and the drastic diminution of HGF levels in bone
marrow plasma by inducing remission.
Materials and methods
Patients
Thirty patients with leukaemia were studied. Mean age was
49.1 years, with a range from 21 to 75. The diagnosis was
based on cell morphology and genetic markers. The clinical
data for the patients are shown in Table I. The subtypes and
numbers of cases were: 20 cases of acute myeloid leukaemia
(AML) [Ml (n = 3), M2 (n = 4), M3 (n = 4), M4 (n = 3),
M5 (n = 2)], four cases of myeloid leukaemic transformation
from myelodysplastic syndrome (LT-MDS), five cases of
chronic myeloid leukaemia (CML) and five cases of acute
lymphoid leukaemia (ALL). Liver function was normal in all
cases. Samples were also obtained from four patients with
iron deficiency anemia (IDA) and 26 haematologically nor-
mal subjects without any disease. All samples were taken
with informed consent.
Determination ofHGF concentration
Bone marrow samples were obtained in polypropylene tubes
containing disodium ethylenediaminetetraacetate (EDTA)
from iliac bones by aspiration; they were immediately cent-
rifuged at 4°C. The supernatants were then stored at - 40°C
until assayed. HGF concentrations in blood and bone mar-
row plasma were determined by using enzyme-linked
immunosorbent assay (ELISA) as described previously
(Nishino et al., 1991). Briefly, standard human HGF or
samples with unknown concentrations of HGF were
dispensed into a 96-well microtitre plate coated with a
monoclonal antibody against human HGF. After incubation
for 1 h, it was washed three times with phosphate-buffered
saline plus 0.05% Tween-20 (PBS-T). After the addition of a
0.1 ml aliquot of a polyclonal antibody against human HGF,
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Table I Clinical features of patients and bone marrow plasma HGF concentra-
tions
FAB Bone marrow plasma
classification Case Age/Sex HGF concentration (ngml'1)
AML
AML Mi MO0 64/M 30.33
AML Mi M06 58/M 0.56
AML M1 M17 44/F 0.62
AML M2 M03 38/F 15.61
AML M2 M04 34/M 3.19
AML M2 M05 51/M 1.34
AML M2 M16 25/F 2.99
AML M3 MiO 49/M 83.40
AML M3 Mul 57/F 10.96
AML M3 M12 44/M 20.00
AML M3 M15 61/M 15.20
AML M4 M02 54/F 7.12
AML M4 M13 29/F 44.00
AML M4 M18 44/M 4.52
AML M5 Mi9 58/F 102.6
AML M5 M20 23/M 4.64
LT-MDS M07 62/M 6.12
LT-MDS M08 55/M 14.70
LT-MDS M09 71/F 39.15
LT-MDS M14 64/M 1.72
ALL
ALL LI L02 75/F 0.20
ALL LI L03 57/M 0.86
ALL LI L04 42/M 0.74
ALL LI L05 58/M 0.64
ALL L3 LOI 66/M 1.01
CML
CML CMOi 51/F 6.45
CML CM02 22/F 7.06
CML CM03 41/F 8.09
CML CM04 64/F 8.58
CML CM05 21/M 5.68
the plate was incubated for 1 h, then washed three times with
PBS-T. After the addition of 0.2 ml of diluted goat (anti-
rabbit immunoglobulin) IgG-peroxidase conjugate, the plate
was incubated for 1 h and then washed. An aliquot (0.1 ml)
of 0.25% o-phenylenediamine was added and the plate
allowed to stand for 10 min. After the reaction was stopped
by the addition of 0.1 ml of 1.0 N sulphuric acid, the absor-
bance was measured at 492 nm by an automatic plate reader
with a reference wavelength of 690 nm. The detection limit of
this assay is 0.1Ongml-'.
Northern blot analysis
Mononuclear cells were prepared from heparinised fresh
peripheral blood or bone marrow samples by density
gradient centrifugation on Ficoll-Metrizoate (Nyegaard,
Norway; density = 1.077 g ml-'). Total cellular RNA was
extracted from these cells by the acid guanidium-thiocyanate
phenol-chloroform method (Chomoczynski and Sacchi,
1987). For Northern blot analysis, 20 tLg of total RNA was
separated by electrophoresis on 1% agarose gel containing
formaldehyde, transferred to nylon membranes (Hybond-N,
Amersham International, Buckinghamshire, UK) by capillary
action, and fixed. Human HGF (Nishino et al., 1991) or rat
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Fort
et al., 1985) cDNA were labelled with [a-32P]dCTP (sp. act.
111 TBq mmol-'; NEN Research Products, Boston, MA,
USA) using hexadeoxynucleotide random primers (Amer-
sham International). The membranes were hybridised with
32P-labelled HGF or GAPDH cDNA as probes in 50%
formamide, 3 x SSC (1 x SSC, 0.15 M sodium chloride plus
0.015M sodium citrate, pH 7.4), 50mM Tris-HCI (pH 7.5),
0.1% sodium dodecyl sulphate (SDS), 20lg ml-' tRNA,
20tig ml- boiled salmon sperm DNA, 1 mM EDTA and
1 x Denhardt (0.02% bovine serum albumin, 0.02%
polyvinylpyrrolidone and 0.02% Ficoll) for 40 h at 37°C. The
nylon membranes were washed with 2 x SSC, 1% SDS, and
1 x Denhardt; at 37°C for 1 h, followed by 0.1 x SSC and
1% SDS at 50°C for 1 h and then autoradiographed using
intensifying screens at - 80°C.
Primary cell culture
Mononuclear cells from peripheral blood or bone marrow
samples were inoculated at 2 x 106 cells per ml in RPMI-
1640 medium (Flow Laboratories, Irvine, UK) supplemented
with 10% heat-inactivated fetal calf serum (FCS: Gibco,
Grand Island, NY, USA) in 5% carbon dioxide-water-
saturated atmosphere at 37°C. The culture supernatant was
collected every day for the measurement for its HGF levels.
HGF concentrations were determined by using ELISA.
Statistics
All data were presented as means ± standard error (s.e.).
Statistical analysis of HGF concentrations among the series
of patients was performed using one-way analysis of variance
(ANOVA) and multiple comparison (Scheffe type) for the
assessment of means. HGF concentrations on the initial
leukaemic state and the remission state were compared with
the two-tailed Student's t-test for paired data. Differences
were considered to be significant when P-values were less
than 0.05. Analysis was carried out using the Stat View
program (Abacus Concepts, Berkeley, CA, USA).
Results
Determination ofHGF levels in bone marrow plasma and
peripheral blood
HGF concentrations in bone marrow plasma are summarised
in Figure 1. In bone marrow plasma from 26 normal sub-
jects, HGF level was 0.92 ± 0.09 (mean ± s.e.) ng ml-' with a0
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Figure 1 Bone marrow plasma HGF concentrations in normal
subjects (n = 26), patients with IDA (n = 4), and patients with
leukaemia (AML, n = 20; ALL, n = 5; CML, n = 5). HGF con-
centrations were determined by ELISA as described in Materials
and methods.
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range from 0.29 to 1.99 ng ml-'. In patients with AML
(n = 20) and CML (n = 5), HGF concentrations were
20.44 ± 6.26 ng ml-' (range from 0.56 to 102.6 ngml') and
7.17 ± 0.53 ng ml-' (range from 5.68 to 8.58 ng ml-') respec-
tively. These values were both significantly greater than that
for normal subjects (P<0.01). HGF concentrations in
patients with ALL (n = 5) and IDA (n = 4) were
0.69 ± 0.14 ng ml-' (range from 0.20 to 1.01 ng ml-') and
0.90 ± 0.29 ng ml-' (range from 0.58 to 1.76 ng ml-') respec-
tively. HGF levels were significantly lower in peripheral
blood than those in bond marrow plasma, as reflected by the
comparison of HGF levels in both specimens obtained at the
same time in nine cases (data not shown).
Northern blot analysis
To confirm the possibility of HGF production in leukaemic
blast cells from AML and CML patients, Northern blot
analysis of total cellular RNA from leukaemic blast cells
using a human HGF cDNA as a probe was performed.
Figure 2 shows a single band of 6.0 kb HGF transcript in
patients with AML and CML. Supporting the specificity of
HGF production for the cells in the myeloid lineage, very
low expression of the HGF transcript was obtained from
ALL patients. Basal levels of HGF mRNA, as semiquan-
titated by laser densitometer, broadly correlated with its
protein levels in bone marrow plasma (data not shown).
HGFproduction byfresh leukaemic blast cells
To further elucidate the HGF production by leukaemic blast
cells, mononuclear cells, obtained from bone marrow and
peripheral blood of four cases (M06, MIO, M13, CM03),
were cultured for 5 days. Figure 3 shows the HGF produc-
tion of fresh leukaemic blast cells. The cells from three cases
(M10, M13, CM03) produced HGF in a time-dependent
manner. Furthermore, the rates of HGF production in these
patients were correlated with their HGF levels in bone mar-
row plasma (data not shown).
Diminution ofHGFlevels in bone marrow plasma by induction
ofremission
We also examined the change of HGF levels by inducing
remission. In six patients (M03, MO0, MI1, M12, M13, M15)
with AML, morphologically complete remission was ob-
tained after chemotherapy. Figure 4 shows a comparison of
bone marrow HGF levels between the leukaemic and the
Figure 2 Northern blot analysis of the human HGF mRNA in
fresh leukaemic blast cells. Total RNAs (20 g) prepared from
patients with leukaemia were electrophoresed, transferred and
hybridised with human HGF cDNA or rat GAPDH cDNA as
probes. The various lanes contained RNAs extracted from the
indicated samples. (a) Cases MOI, M02, M03, M04, M05, M06,
M07, M08, M09 (AML) and LOI, L02 (ALL). (b) Cases M03,
M10, Ml1, M12, M13 (AML), L03, L04, L05 (ALL), and CM01,
CM02, CM03 (CML).
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Figure 3 Continuous HGF production of fresh leukaemic blast
cells. Mononuclear cells from peripheral blood or bone marrow
samples ofpatients with leukaemia were cultured at a starting cell
density of 2 x 106 cells/ml-' for 5 days. The amount of HGF in
cultured medium was measured by ELISA as described in
Materials and methods. The cases are: MIO (a), M13 (0),
CM03 (A), M06 (A).
remission state. Bone marrow HGF levels were significantly
decreased in the remission state.
Discussion
In the present study, we have shown that HGF levels in bone
marrow plasma from AML and CML patients were
significantly higher than those for normal subjects. These
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Figure 4 Comparison of bone marrow plasma HGF concentra-
tions in the initial leukaemic state and in the complete remission
state after chemotherapy in six cases (M03, M10, Ml1, M12,
M13, M15). HGF concentrations were determined by ELISA as
described in Materials and methods.
results are in good agreement with the recent short report by
Nakamura et al. (1994a). We have not observed any obvious
correlation between HGF production and FAB classification.
As shown in Table I, there was a large individual variation in
bone marrow HGF levels even in the same FAB class. How-
ever, high HGF levels were observed in all M3, M4, and M5
cases that we tested. As the reason for high HGF levels, we
have shown that leukaemic blast cells from patients with
AML and CML produced HGF constitutively. In support of
this hypothesis, we have observed a significant diminution of
HGF levels in bone marrow plasma after eradication of
leukaemic blast cells by successful treatment. Furthermore,
we have found that bone marrow HGF levels in patients with
ALL remained low within the value for normal subjects.
These results together strongly suggest that HGF was pro-
duced specifically by myeloid lineage leukaemia (AML or
CML) cells, but not by lymphoid lineage leukaemia (ALL)
cells. This hypothesis was further supported by Northern blot
analysis suggesting the positive staining of 6.0 kb HGF trans-
cripts in the cells from AML and CML patients but not from
ALL patients (Figure 2). We have previously reported that
HGF production is induced in the promyelocytic leukaemia
cell line, HL-60, by 12-o-tetradecanoyl phorbol 13-acetate
(TPA), but not by dimethyl sulphoxide (DMSO) (Nishino et
al., 1991). It is well known that HL-60 cells are differentiated
into macrophages in the presence of TPA and into
granulocytes in the presence of DMSO. Noji et al. (1990)
have shown by in situ hybridisation that endothelial cells and
Kupffer cells are HGF-producing cells in damaged liver.
Kupffer cells are macrophages that reside in the liver and
belong to the myeloid lineage. Recently, we reported release
of HGF from rheumatoid synovial fluid cells, which contains
a large number of polymorphonuclear cells (Yukioka et al.,
1994b). These results suggest that some populations of
myeloid lineage cells may produce HGF. This notion is
further supported by the recent report (Nakamura et al.,
1994) demonstrating the constitutive production of HGF by
myeloid lineage leukaemic cell lines (KCL-22, KG-lA and
KG-1), although all myeloid leukaemic blast cells do not
produce HGF.
Various cytokines are produced by leukaemic cells. Some
cytokines stimulate autocrine growth of leukaemic blast cells.
Several reports have shown that HGFR/c-met mRNA is
expressed in murine myeloid progenitor cell lines (Kmiecik et
al., 1992; Mizuno et al., 1993). Therefore, HGF may also
play a role as an autocrine growth factor in leukaemic blast
cells. To explore this possibility, we have investigated the
expression of the HGFR/c-met gene in cases (M03, M09,
M1O, M11, M12, M13 as AML and CMO1 as CML), poly A
RNAs of bone marrow blast cells from patients with AML
and CML were analysed. However, HGFR/c-met-specific
mRNA was not detected in any case (data not shown).
Furthermore, recombinant human HGF had no effect on
proliferation of blast cells from patients with AML (data not
shown). Jucker et al. (1994) have reported that HGFR/c-met
mRNA is overexpressed in some cases of leukaemia and
lymphoma. Since they have demonstrated that expression of
the HGFR/c-met gene is detected in only I AML case out of
29 leukaemias, HGF still might be an autocrine growth
factor in a few cases of AML. Kmiecik et al. (1992) have
reported that HGFR/c-met mRNA and protein are expressed
in the progenitor-enriched murine bone marrow cells and
that HGF has a synergistic effect with interleukin 3 (IL-3)
and granulocyte-macrophage colony-stimulating factor (GM-
CSF) to stimulate colony formation of bone marrow cells.
Galimi et al. (1994) have reported that HGFR/c-met is exp-
ressed in human CD34-positive haematopoietic progenitor
cells and that HGF stimulates erythroid and multipotent
progenitor cells in the presence of cytokines such as eryth-
ropoietin, IL-3 and GM-CSF. During embryonic develop-
ment, haematopoiesis originates in the yolk sac, then moves
to the liver and spleen and finally settles in the bone marrow.
Of interest, HGF and/or HGFR/c-met are expressed in the
fetal liver (Selden et al., 1990; Hu et al., 1993; Galimi et al.,
1994) and yolk sac (Chan et al., 1988). Recently, Nishino et
al. (1995) have reported that both HGF and HGFR/c-met
mRNA are expressed in the mouse fetal liver in the middle
and late stages when haematopoiesis is most active. These
results suggest that HGF may be a modulator in early
haematopoietic processes. Our findings and the findings of
others indicating HGF production by some populations of
myeloid lineage ,cells, HGF may have positive-feedback
effects on the growth of haematopoietic progenitors.
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